More News
28 November 2018
Genentech Acquires Jecure Therapeutics27 November 2018
Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer27 November 2018
Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company26 November 2018
REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector26 November 2018
Rheostat Therapeutics Announces $23 Million Series A Financing To Develop Potential Treatments for Neurodegenerative Diseases23 November 2018
Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas21 November 2018
LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases20 November 2018
Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL20020 November 2018
GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program19 November 2018
Alvotech and Fuji Pharma Enter into Exclusive Partnership for Development and Commercialization of Biosimilars in Japan16 November 2018
MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys’s Novel Immuno-Oncology Agent MOR21015 November 2018
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies15 November 2018
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag15 November 2018
Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease13 November 2018
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer13 November 2018
MaxCyte Announces Research Agreement with Kite, a Gilead Company13 November 2018
Medigene AG: Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T Cell Receptor13 November 2018
Sobi™ to acquire Synagis® US rights from AstraZeneca – creates a platform for global growth11 November 2018
BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company9 November 2018
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology8 November 2018
Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics8 November 2018
Saniona signs option agreement with Initiator Pharma6 November 2018
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines5 November 2018
Grünenthal Acquires Global Rights for QutenzaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports